Your browser doesn't support javascript.
loading
Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14).
Kalff, Anna; Khong, Tiffany; Ramachandran, Malarmathy; Ho, P Joy; Mollee, Peter; D'Rozario, James; Taylor, Kerry; Estell, Jane; Norton, Sam; Kemp, Roslyn; Mitchell, Andrew J; Reynolds, John; Kennedy, Nola; Quach, Hang; Spencer, Andrew.
Afiliación
  • Kalff A; Malignant Haematology and Stem Cell Transplantation, Alfred Hospital, Melbourne, Victoria, Australia; Myeloma Research Group, Australian Centre for Blood Diseases, Alfred Hospital-Monash University, Melbourne, Victoria, Australia; Department of Clinical Haematology, Monash University, Clayton, Victo
  • Khong T; Malignant Haematology and Stem Cell Transplantation, Alfred Hospital, Melbourne, Victoria, Australia; Myeloma Research Group, Australian Centre for Blood Diseases, Alfred Hospital-Monash University, Melbourne, Victoria.
  • Ramachandran M; Malignant Haematology and Stem Cell Transplantation, Alfred Hospital, Melbourne, Victoria, Australia; Myeloma Research Group, Australian Centre for Blood Diseases, Alfred Hospital-Monash University, Melbourne, Victoria.
  • Ho PJ; Royal Prince Alfred Hospital, Sydney.
  • Mollee P; Princess Alexandra Hospital and University of Queensland, Brisbane.
  • D'Rozario J; The Canberra Hospital, Canberra.
  • Taylor K; Icon Cancer Centre, Brisbane.
  • Estell J; Concord Repatriation General Hospital, University of Sydney, Sydney.
  • Norton S; Nanix Ltd., Dunedin, New Zealand; Department of Microbiology and Immunology, University of Otago.
  • Kemp R; Department of Microbiology and Immunology, University of Otago.
  • Mitchell AJ; Materials Characterisation and Fabrication Platform, Department of Chemical Engineering, University of Melbourne.
  • Reynolds J; Department of Epidemiology and Preventive Medicine, Alfred Health - Monash University, Melbourne, Victoria.
  • Kennedy N; Malignant Haematology and Stem Cell Transplantation, Alfred Hospital, Melbourne, Victoria.
  • Quach H; Faculty of Medicine, University of Melbourne, St Vincent's Hospital Melbourne, Australia [on behalf of The Australasian Leukaemia and Lymphoma Group (ALLG)].
  • Spencer A; Malignant Haematology and Stem Cell Transplantation, Alfred Hospital, Melbourne, Victoria, Australia; Myeloma Research Group, Australian Centre for Blood Diseases, Alfred Hospital-Monash University, Melbourne, Victoria, Australia; Department of Clinical Haematology, Monash University, Clayton, Victo
Haematologica ; 107(1): 321-325, 2022 01 01.
Article en En | MEDLINE | ID: mdl-34587718
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Mieloma Múltiple Límite: Humans Idioma: En Revista: Haematologica Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Mieloma Múltiple Límite: Humans Idioma: En Revista: Haematologica Año: 2022 Tipo del documento: Article